Elanco Animal Health (NYSE:ELAN) Rating Increased to Outperform at William Blair

Elanco Animal Health (NYSE:ELAN - Get Free Report) was upgraded by William Blair from a "market perform" rating to an "outperform" rating in a report issued on Thursday, MarketBeat reports.

A number of other research firms have also weighed in on ELAN. Morgan Stanley cut their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Barclays reduced their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. UBS Group lowered their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Piper Sandler dropped their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Finally, Stifel Nicolaus raised their price target on Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Monday, May 19th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Elanco Animal Health currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.17.

Elanco Animal Health Price Performance

NYSE ELAN traded up $0.02 during trading hours on Thursday, reaching $14.32. The company's stock had a trading volume of 5,611,213 shares, compared to its average volume of 5,164,207. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.46 and a current ratio of 2.71. The company's 50-day moving average is $12.39 and its two-hundred day moving average is $11.51. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $15.78. The stock has a market cap of $7.11 billion, a PE ratio of 19.34, a PEG ratio of 2.80 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the business earned $0.34 earnings per share. The company's quarterly revenue was down 1.0% on a year-over-year basis. Analysts forecast that Elanco Animal Health will post 0.91 EPS for the current year.

Institutional Trading of Elanco Animal Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC boosted its position in shares of Elanco Animal Health by 28.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock worth $124,000 after buying an additional 2,264 shares during the period. Dimensional Fund Advisors LP lifted its position in Elanco Animal Health by 6.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock worth $216,774,000 after acquiring an additional 1,074,274 shares in the last quarter. Jones Financial Companies Lllp lifted its position in Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares in the last quarter. Yousif Capital Management LLC purchased a new position in Elanco Animal Health in the 1st quarter worth approximately $119,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Elanco Animal Health by 9.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 117,611 shares of the company's stock valued at $1,424,000 after acquiring an additional 9,928 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.